These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 28242239)
1. Role of Toll-like receptor 4 in drug-drug interaction between paclitaxel and irinotecan in vitro. Mallick P; Basu S; Moorthy B; Ghose R Toxicol In Vitro; 2017 Jun; 41():75-82. PubMed ID: 28242239 [TBL] [Abstract][Full Text] [Related]
2. Role of Adaptor Protein Toll-Like Interleukin Domain Containing Adaptor Inducing Interferon β in Toll-Like Receptor 3- and 4-Mediated Regulation of Hepatic Drug Metabolizing Enzyme and Transporter Genes. Shah P; Omoluabi O; Moorthy B; Ghose R Drug Metab Dispos; 2016 Jan; 44(1):61-7. PubMed ID: 26470915 [TBL] [Abstract][Full Text] [Related]
3. Regulation of hepatic drug-metabolizing enzyme genes by Toll-like receptor 4 signaling is independent of Toll-interleukin 1 receptor domain-containing adaptor protein. Ghose R; White D; Guo T; Vallejo J; Karpen SJ Drug Metab Dispos; 2008 Jan; 36(1):95-101. PubMed ID: 17932222 [TBL] [Abstract][Full Text] [Related]
4. Irinotecan decreases intestinal UDP-glucuronosyltransferase (UGT) 1A1 via TLR4/MyD88 pathway prior to the onset of diarrhea. Tao G; Dagher F; Li L; Singh R; Hu M; Ghose R Food Chem Toxicol; 2022 Aug; 166():113246. PubMed ID: 35728726 [TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics of irinotecan metabolism and transport: an update. Smith NF; Figg WD; Sparreboom A Toxicol In Vitro; 2006 Mar; 20(2):163-75. PubMed ID: 16271446 [TBL] [Abstract][Full Text] [Related]
6. Irinotecan-Induced Gastrointestinal Dysfunction and Pain Are Mediated by Common TLR4-Dependent Mechanisms. Wardill HR; Gibson RJ; Van Sebille YZ; Secombe KR; Coller JK; White IA; Manavis J; Hutchinson MR; Staikopoulos V; Logan RM; Bowen JM Mol Cancer Ther; 2016 Jun; 15(6):1376-86. PubMed ID: 27197307 [TBL] [Abstract][Full Text] [Related]
7. Effects of green tea compounds on irinotecan metabolism. Mirkov S; Komoroski BJ; Ramírez J; Graber AY; Ratain MJ; Strom SC; Innocenti F Drug Metab Dispos; 2007 Feb; 35(2):228-33. PubMed ID: 17108060 [TBL] [Abstract][Full Text] [Related]
8. Determination of drug interactions occurring with the metabolic pathways of irinotecan. Charasson V; Haaz MC; Robert J Drug Metab Dispos; 2002 Jun; 30(6):731-3. PubMed ID: 12019202 [TBL] [Abstract][Full Text] [Related]
9. TLR4 and NFκB signaling is critical for taxol resistance in ovarian carcinoma cells. Sun NK; Huang SL; Chang TC; Chao CC J Cell Physiol; 2018 Mar; 233(3):2489-2501. PubMed ID: 28771725 [TBL] [Abstract][Full Text] [Related]
10. Impact of obesity on accumulation of the toxic irinotecan metabolite, SN-38, in mice. Mallick P; Shah P; Gandhi A; Ghose R Life Sci; 2015 Oct; 139():132-8. PubMed ID: 26334566 [TBL] [Abstract][Full Text] [Related]
12. Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective cross-over drug-drug interaction study. van der Bol JM; Loos WJ; de Jong FA; van Meerten E; Konings IR; Lam MH; de Bruijn P; Wiemer EA; Verweij J; Mathijssen RH Eur J Cancer; 2011 Apr; 47(6):831-8. PubMed ID: 21216137 [TBL] [Abstract][Full Text] [Related]
14. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Han JY; Lim HS; Yoo YK; Shin ES; Park YH; Lee SY; Lee JE; Lee DH; Kim HT; Lee JS Cancer; 2007 Jul; 110(1):138-47. PubMed ID: 17534875 [TBL] [Abstract][Full Text] [Related]
15. Role for drug transporters beyond tumor resistance: hepatic functional imaging and genotyping of multidrug resistance transporters for the prediction of irinotecan toxicity. Kroetz DL J Clin Oncol; 2006 Sep; 24(26):4225-7. PubMed ID: 16895999 [No Abstract] [Full Text] [Related]
16. The Cancer Chemotherapeutic Paclitaxel Increases Human and Rodent Sensory Neuron Responses to TRPV1 by Activation of TLR4. Li Y; Adamek P; Zhang H; Tatsui CE; Rhines LD; Mrozkova P; Li Q; Kosturakis AK; Cassidy RM; Harrison DS; Cata JP; Sapire K; Zhang H; Kennamer-Chapman RM; Jawad AB; Ghetti A; Yan J; Palecek J; Dougherty PM J Neurosci; 2015 Sep; 35(39):13487-500. PubMed ID: 26424893 [TBL] [Abstract][Full Text] [Related]
17. TLR4 is a novel determinant of the response to paclitaxel in breast cancer. Rajput S; Volk-Draper LD; Ran S Mol Cancer Ther; 2013 Aug; 12(8):1676-87. PubMed ID: 23720768 [TBL] [Abstract][Full Text] [Related]
18. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Reese MJ; Savina PM; Generaux GT; Tracey H; Humphreys JE; Kanaoka E; Webster LO; Harmon KA; Clarke JD; Polli JW Drug Metab Dispos; 2013 Feb; 41(2):353-61. PubMed ID: 23132334 [TBL] [Abstract][Full Text] [Related]
19. In Vitro Approaches to Study Regulation of Hepatic Cytochrome P450 (CYP) 3A Expression by Paclitaxel and Rifampicin. Ghose R; Mallick P; Taneja G; Chu C; Moorthy B Methods Mol Biol; 2016; 1395():55-68. PubMed ID: 26910068 [TBL] [Abstract][Full Text] [Related]
20. Lessons learned from the irinotecan metabolic pathway. Ma MK; McLeod HL Curr Med Chem; 2003 Jan; 10(1):41-9. PubMed ID: 12570720 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]